GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (NAS:NSPR) » Definitions » Return-on-Tangible-Asset

InspireMD (InspireMD) Return-on-Tangible-Asset : -62.74% (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is InspireMD Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. InspireMD's annualized Net Income for the quarter that ended in Mar. 2024 was $-28.13 Mil. InspireMD's average total tangible assets for the quarter that ended in Mar. 2024 was $44.84 Mil. Therefore, InspireMD's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -62.74%.

The historical rank and industry rank for InspireMD's Return-on-Tangible-Asset or its related term are showing as below:

NSPR' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -181.73   Med: -84.65   Max: -51.9
Current: -53.21

During the past 13 years, InspireMD's highest Return-on-Tangible-Asset was -51.90%. The lowest was -181.73%. And the median was -84.65%.

NSPR's Return-on-Tangible-Asset is ranked worse than
78.26% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: -2.685 vs NSPR: -53.21

InspireMD Return-on-Tangible-Asset Historical Data

The historical data trend for InspireMD's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Return-on-Tangible-Asset Chart

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.58 -76.25 -51.90 -57.46 -55.10

InspireMD Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.39 -55.22 -39.96 -44.27 -62.74

Competitive Comparison of InspireMD's Return-on-Tangible-Asset

For the Medical Devices subindustry, InspireMD's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where InspireMD's Return-on-Tangible-Asset falls into.



InspireMD Return-on-Tangible-Asset Calculation

InspireMD's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-19.916/( (24.653+47.643)/ 2 )
=-19.916/36.148
=-55.10 %

InspireMD's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-28.128/( (47.643+42.028)/ 2 )
=-28.128/44.8355
=-62.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


InspireMD  (NAS:NSPR) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


InspireMD Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of InspireMD's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (InspireMD) Business Description

Traded in Other Exchanges
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Executives
Gary S Roubin director 4300 ROCKMORE RD JACKSON, WYOMING WY 83001
Patrick Verta officer: EVP Clinical/Medical Affairs 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Berman director 735 PALAMAR AVENUE, SUNNYVALE CA 94085
Thomas J Kester director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Paul Stuka director C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
Andrea Tommasoli officer: Chief Operating Officer 22, RUE DE LA PLAGE, COLLONGES AU MONT D OR I0 69660
Shane Thomas Gleason officer: VP Global Marketing 18 NORTHAMPTON PL, COTO DE CAZA CA 92679
Kathryn Arnold director 1136 CHESTNUT AVE., WILMETTE IL 60091
Marvin Slosman director, officer: CEO and President 4 MENORAT HAMAOR ST., C/O INSPIREMD, INC., TEL AVIV L3 6744832
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Agustin V Gago officer: EVP, Chief Commercial Officer 256 JERUSALEM AVE, MASSAPEQUA NY 11758
Eric L. Olson officer: VP of Global Sales Operations C/O INSPIREMD, INC., 800 BOYLSTON STREET, 16TH FLOOR, BOSTON MA 02199
Campbell Rogers director C/O INSPIREMD, INC., 800 BOYLSTON STREET, SUITE 16041, BOSTON MA 02199
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Eyal Weinstein director C/O LEOREX LTD., P.O.B. 15067 MATAM, HAIFA L3 31905

InspireMD (InspireMD) Headlines

From GuruFocus

InspireMD Announces Private Placement of Up to $113.6 Million

By sperokesalga sperokesalga 05-15-2023